SAN DIEGO

圣迭戈

,

，

June 19, 2026

2026年6月19日

/PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, and MOTE Therapeutics, a preclinical-stage biotech company developing a novel targeted LNP delivery platform and

/PRNewswire/ -- 法鹏生物制药（Fapon Biopharma）是一家处于临床阶段的生物技术公司，致力于创新治疗性抗体和融合蛋白；MOTE Therapeutics 是一家处于临床前阶段的生物技术公司，正在开发一种新型靶向脂质纳米颗粒（LNP）递送平台，以及

in vivo

体内

CAR-T therapies, today announced their participation in the BIO International Convention 2026, taking place June 22–25 at the San Diego Convention Center. Both companies are members of Fapon Group

CAR-T疗法公司今日宣布将参加2026年BIO国际大会，该会议将于6月22日至25日在圣地亚哥会议中心举行。两家公司均为法朋集团成员。

.

。

They will present their dual-targeting

他们将展示他们的双靶向

(CD19×BCMA)

(CD19×BCMA)

, dual-platform

，双平台

(TCE +

(TCE +

in vivo

体内

CAR-T)

CAR-T

franchise designed to achieve

旨在实现的特许经营

deep and durable B-cell depletion

深度且持久的B细胞耗竭

through complementary therapeutic modalities, with both assets advancing toward human trials in the next six months.

通过互补的治疗方式，这两项资产均将在未来六个月内推进至人体临床试验阶段。

The companies will exhibit at Booth 5435-2 in the Shanghai Pudong Pavilion, highlighting their complementary technology platforms, innovative pipeline across immuno-oncology and autoimmune diseases, and global partnership opportunities.

这些公司将在上海浦东馆的5435-2号展位展出，重点展示其互补的技术平台、在免疫肿瘤学和自身免疫疾病领域的创新研发管线，以及全球合作机会。

Two proprietary technology platforms serve as the engine behind this pipeline. Fapon Biopharma brings its proprietary

两大专有技术平台构成了这一产品管线的核心引擎。法鹏生物制药带来了其专有的

VHH human-cynomolgus cross-binding T-cell engager platform

VHH人-食蟹猴交叉结合T细胞衔接器平台

, an innovative approach designed to overcome developability and therapeutic window constraints associated with traditional multi-specific immune cell engagers, featuring human-cynomolgus cross-reactivity, scalable GMP manufacturing with proven cell line development, and versatile molecular design. MOTE Therapeutics' breakthrough .

，这是一种创新方法，旨在克服与传统多特异性免疫细胞衔接器相关的可开发性和治疗窗口限制，具备人-食蟹猴交叉反应性、经证实的细胞系开发支持的可扩展GMP生产，以及灵活的分子设计。MOTE Therapeutics的突破性成果。

mobilize™ targeted LNP (tLNP) platform

mobilize™ 靶向脂质纳米颗粒 (tLNP) 平台

is a next-generation

是下一代

in vivo

体内

gene delivery system that enables cell-specific targeted delivery and extrahepatic tissue distribution through a non-covalent, modular surface functionalization approach that requires no chemical conjugation.

一种基因递送系统，通过无需化学偶联的非共价模块化表面功能化方法，实现细胞特异性靶向递送及肝外组织分布。

The companies' B-cell depletion franchise takes center stage at BIO 2026. This franchise features two differentiated programs targeting CD19 and BCMA, designed to deliver potent and sustained B-cell depletion: FPE024, a potential best-in-class

该公司的B细胞清除产品组合在2026年生物技术大会（BIO 2026）上成为焦点。该组合包含两个差异化项目，分别靶向CD19和BCMA，旨在实现强效且持久的B细胞清除：FPE024是一款具备同类最佳潜力的

CD19×BCMA×CD3

CD19×BCMA×CD3

tri-specific T-cell engager for autoimmune indications, with IND filing targeted Q1 2027; and MTX001, a

用于自身免疫适应症的三特异性T细胞衔接器，目标于2027年第一季度提交新药临床试验申请（IND）；以及MTX001，一种

CD19×BCMA

CD19×BCMA

in vivo

体内

CAR-T

CAR-T

program powered by the mobilize™ tLNP platform, with an investigator-initiated first-in-human study expected in Q4 2026.

该项目由 mobilize™ tLNP 平台提供支持，预计将于 2026 年第四季度开展一项研究者发起的首次人体临床试验。

In addition to the B-cell depletion franchise, the companies have built a robust pipeline spanning discovery, preclinical and clinical stages. Leading the clinical-stage pipeline is FP008, a global first-in-class

除了B细胞清除产品系列外，两家公司还建立了涵盖发现、临床前和临床阶段的强大研发管线。处于临床阶段管线领先地位的是FP008，这是一款全球首创的

PD1×IL10M

PD1×IL10M

fusion protein for immuno-oncology, currently in Phase I development with key readout anticipated in 2026. FP012 is a global first-in-class

用于肿瘤免疫治疗的融合蛋白，目前处于I期开发阶段，预计2026年将公布关键数据。FP012是一款全球首创的同类首创药物

TL1A×IL10MM

TL1A×IL10MM

fusion protein for inflammatory bowel disease and other inflammatory and autoimmune indications. FPE021 is a potential best-in-class

用于炎症性肠病及其他炎症和自身免疫适应证的融合蛋白。FPE021 是一种潜在的同类最佳药物

CDH17-targeting T-cell engager

靶向CDH17的T细胞衔接器

with a second co-stimulation signal for gastrointestinal tract cancers. Both FP012 and FPE021 are entering IND-enabling CMC/GLP toxicology in 2026.

针对胃肠道肿瘤的第二共刺激信号。FP012和FPE021均将于2026年进入支持新药临床试验申请（IND）的CMC/GLP毒理学研究阶段。

Attendees interested in the science behind these programs can gain deeper insights during a dedicated company presentation, titled

对这些项目背后的科学原理感兴趣的与会者，可以在一场题为

'Building a Dual-Targeting / Dual-Platform Franchise for B-Cell Immunotherapy'

“构建用于B细胞免疫疗法的双靶点/双平台产品管线”

on Monday, June 22 at 4:30 PM PT in Room 3. The session will detail the technical design, development roadmap and commercial potential of the companies' integrated dual-platform strategy for B-cell immunotherapy.

6月22日（星期一）下午4:30（太平洋时间），在3号会议室。会议将详细介绍公司针对B细胞免疫治疗的集成双平台战略的技术设计、开发路线图及商业潜力。

Fapon Biopharma and MOTE Therapeutics are actively pursuing flexible partnership models, including co-development and licensing. Industry partners, investors and biotech peers are invited to schedule one-on-one meetings in advance via email at

法鹏生物制药与MOTE Therapeutics正积极寻求灵活的合作模式，包括共同开发和许可授权。诚邀行业合作伙伴、投资者及生物科技同行通过电子邮件提前预约一对一会议，邮箱地址为

[email protected]

[email protected]

(Americas, Europe and other regions),

（美洲、欧洲及其他地区）

[email protected]

[email protected]

(Asia-Pacific), or

（亚太地区），或

[email protected]

[email protected]

, or visit

，或访问

Booth 5435-2

展位 5435-2

during exhibit hours to discuss how these differentiated platforms and pipeline assets can support their development goals.

在展览期间，讨论这些差异化平台和管线资产如何支持他们的开发目标。

About Fapon Biopharma

关于法朋生物制药

Fapon Biopharma specializes in discovering and developing biologics for cancer treatment, autoimmune diseases and other therapeutic areas with significant unmet medical needs. Leveraging cutting-edge technologies, the company has built advanced drug discovery platforms, including an antibody discovery platform based on globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a TCE platform based on cross-species CD3-VHH of human and monkey.

法鹏生物制药专注于发现和开发用于治疗癌症、自身免疫性疾病以及其他存在重大未满足医疗需求的治疗领域的生物制剂。凭借尖端技术，公司建立了先进的药物发现平台，包括基于全球领先的哺乳动物细胞展示技术的抗体发现平台、IL-10M融合蛋白生成平台，以及基于人猴跨物种CD3-VHH的双特异性T细胞接合器（TCE）平台。

With a differentiated pipeline of leading drug candidates, Fapon Biopharma has established end-to-end capabilities covering the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, the company strives to deliver safer, more efficacious, affordable, and accessible biologics for patients worldwide..

凭借差异化的领先候选药物管线，法鹏生物制药已建立起涵盖从药物发现、临床前研究、化学制造与控制（CMC）到早期临床开发整个药物研发流程的端到端能力。公司致力于创新，力求为全球患者提供更安全、更有效、更可负担且更易获得的生物制品。

About MOTE Therapeutics

关于MOTE Therapeutics

MOTE Therapeutics is a next-generation RNA therapeutics company focused on solving one of the most fundamental bottlenecks in nucleic acid medicine: delivering RNA payloads — particularly circular RNA (circRNA) — to cells and tissues outside the liver. The company's proprietary mobilize™ platform is a modular, scalable, and chemistry-free system for functionalizing LNPs with cell-targeting specificity.

MOTE Therapeutics 是一家下一代 RNA 治疗公司，致力于解决核酸药物中最基本的瓶颈之一：将 RNA 载荷（尤其是环状 RNA [circRNA]）递送至肝脏以外的细胞和组织。该公司专有的 mobilize™ 平台是一个模块化、可扩展且无需化学修饰的系统，用于赋予脂质纳米颗粒（LNPs）细胞靶向特异性。

It enables targeted circRNA delivery to previously inaccessible cell types, unlocking treatments for intractable diseases such as systemic lupus erythematosus, multiple myeloma, plasma cell leukemia, hematopoietic stem cell disorders and neurodegenerative diseases. Founded by Fapon Group and circular RNA pioneer Dr.

它能够将环状RNA靶向递送至以往难以触及的细胞类型，从而为系统性红斑狼疮、多发性骨髓瘤、浆细胞白血病、造血干细胞疾病和神经退行性疾病等顽固性疾病的治疗开辟新途径。该公司由华大基因集团与环状RNA领域先驱博士共同创立。

Alex Wesselhoeft, MOTE combines cutting-edge delivery science with a global footprint spanning the U.S. and China..

Alex Wesselhoeft，MOTE 将尖端的递送科学与横跨美国和中国的全球布局相结合。

SOURCE Fapon Biopharma

来源：法朋生物制药

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示